Does bempedoic acid reduce cardiovascular events in statin-intolerant patients? In CLEAR Outcomes, bempedoic acid lowered LDL cholesterol and reduced major adverse cardiovascular events versus placebo. Randomised trial · New England Journal of Medicine 2023Reference: Nissen SE, Lincoff AM, Brennan D, et al. N Engl J Med. 2023;388(15):1353-1364. PMID: 36876740. https://pubmed.ncbi.nlm.nih.gov/36876740/ AI-narrated episode. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does bempedoic acid reduce cardiovascular events in statin-intolerant patients?In CLEAR Outcomes, bempedoic acid lowered LDL cholesterol and reduced major adverse cardiovascular events versus placebo.Randomised trial · New England Journal of Medicine 2023Reference: Nissen SE, Lincoff AM, Brennan D, et al. N Engl J Med. 2023;388(15):1353-1364. PMID: 36876740. https://pubmed.ncbi.nlm.nih.gov/36876740/AI-narrated episode. For healthcare professionals; educational only and not medical advice.Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Hormone Insight

CLEAR Outcomes: Statin-intolerant patients | Hormone Insight Podcast

Can levothyroxine be discontinued in older adults with subclinical hypothyroidism? In a pilot randomised trial, stopping low-dose levothyroxine did not change hypothyroid symptoms, tiredness or quality of life over six months compared with continuing treatment. Pilot randomised trial · Endocrine 2025Reference: Maraka S, et al. Discontinuation of levothyroxine therapy in patients with subclinical hypothyroidism: a pilot randomised clinical trial. Endocrine. 2025;90(2):781-792. doi:10.1007/s12020-025-04371-z. PMID: 40736623. https://pubmed.ncbi.nlm.nih.gov/40736623/ AI-narrated episode. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Can levothyroxine be discontinued in older adults with subclinical hypothyroidism?In a pilot randomised trial, stopping low-dose levothyroxine did not change hypothyroid symptoms, tiredness or quality of life over six months compared with continuing treatment.Pilot randomised trial · Endocrine 2025Reference: Maraka S, et al. Discontinuation of levothyroxine therapy in patients with subclinical hypothyroidism: a pilot randomised clinical trial. Endocrine. 2025;90(2):781-792. doi:10.1007/s12020-025-04371-z. PMID: 40736623. https://pubmed.ncbi.nlm.nih.gov/40736623/AI-narrated episode. For healthcare professionals; educational only and not medical advice.Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

LT4 withdrawal: Can we stop levothyroxine? | Hormone Insight Podcast

Is secukinumab effective for active, moderate-to-severe Graves orbitopathy? In a randomised trial, secukinumab did not improve clinical response compared with placebo at 16 weeks. Randomised trial · Journal of Clinical Endocrinology & Metabolism 2026Reference: Wolf J, et al. Secukinumab in moderate-to-severe Graves orbitopathy: a randomised, double-blind, placebo-controlled multicentre study. J Clin Endocrinol Metab. 2026;111(5):1248-1257. doi:10.1210/clinem/dgaf655. PMID: 41362233. https://pubmed.ncbi.nlm.nih.gov/41362233/ AI-narrated episode. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Is secukinumab effective for active, moderate-to-severe Graves orbitopathy?In a randomised trial, secukinumab did not improve clinical response compared with placebo at 16 weeks.Randomised trial · Journal of Clinical Endocrinology & Metabolism 2026Reference: Wolf J, et al. Secukinumab in moderate-to-severe Graves orbitopathy: a randomised, double-blind, placebo-controlled multicentre study. J Clin Endocrinol Metab. 2026;111(5):1248-1257. doi:10.1210/clinem/dgaf655. PMID: 41362233. https://pubmed.ncbi.nlm.nih.gov/41362233/AI-narrated episode. For healthcare professionals; educational only and not medical advice.Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

ORBIT: IL-17 for thyroid eye disease? | Hormone Insight Podcast

Does selenium supplementation benefit people with newly diagnosed Graves' hyperthyroidism? In the GRASS randomised trial, selenium did not improve remission rates or quality of life compared with placebo. Randomised trial · European Thyroid Journal 2026Reference: Cramon P, et al. Selenium supplementation in individuals with newly diagnosed Graves' hyperthyroidism: a double-blind, multicentre RCT. Eur Thyroid J. 2026;15(1). doi:10.1530/ETJ-25-0264. PMID: 41384622. https://pubmed.ncbi.nlm.nih.gov/41384622/ AI-narrated episode. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does selenium supplementation benefit people with newly diagnosed Graves' hyperthyroidism?In the GRASS randomised trial, selenium did not improve remission rates or quality of life compared with placebo.Randomised trial · European Thyroid Journal 2026Reference: Cramon P, et al. Selenium supplementation in individuals with newly diagnosed Graves' hyperthyroidism: a double-blind, multicentre RCT. Eur Thyroid J. 2026;15(1). doi:10.1530/ETJ-25-0264. PMID: 41384622. https://pubmed.ncbi.nlm.nih.gov/41384622/AI-narrated episode. For healthcare professionals; educational only and not medical advice.Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

GRASS: Selenium in Graves' | Hormone Insight Podcast

What happens at 5 years of follow-up with thyroidectomy without radioiodine in patients with low-risk thyroid cancer? In patients with low-risk differentiated thyroid cancer, a follow-up strategy without radioiodine was non-inferior to postoperative radioiodine at 5 years. Randomized trial · Lancet Diabetes Endocrinol 2025Reference: Leboulleux. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial. The Lancet Diabetes & Endocrinology. 2025;13(1):38–46. doi:10.1016/S2213-8587(24)00276-6. PMID:39586309. Chapters0:00 Intro0:38 The trial3:19 My take3:50 Outro Read the structured trial summary at https://hormoneinsight.com AI narration is used. This podcast is intended for healthcare professionals only. It is educational, not medical advice. Views expressed are the presenter’s own and do not necessarily reflect those of any institution he works with. Hormone Insight: https://hormoneinsight.comApple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

What happens at 5 years of follow-up with thyroidectomy without radioiodine in patients with low-risk thyroid cancer?In patients with low-risk differentiated thyroid cancer, a follow-up strategy without radioiodine was non-inferior to postoperative radioiodine at 5 years.Randomized trial · Lancet Diabetes Endocrinol 2025Reference: Leboulleux. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial. The Lancet Diabetes & Endocrinology. 2025;13(1):38–46. doi:10.1016/S2213-8587(24)00276-6. PMID:39586309.Chapters0:00 Intro0:38 The trial3:19 My take3:50 OutroRead the structured trial summary at https://hormoneinsight.comAI narration is used. This podcast is intended for healthcare professionals only. It is educational, not medical advice. Views expressed are the presenter’s own and do not necessarily reflect those of any institution he works with.Hormone Insight: https://hormoneinsight.comApple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

ESTIMABL2: No radioiodine at 5 years | Hormone Insight Podcast

After thyroidectomy for low-risk differentiated thyroid cancer, is omission of postoperative radioiodine non-inferior to ablation? In the IoN randomised trial, omission of postoperative radioiodine was noninferior to ablation for 5-year recurrence-free survival. Randomised multicentre non-inferiority trial · The Lancet 2025Reference: Mallick U, et al. Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN). Lancet. 2025;406(10498):52-62. doi:10.1016/S0140-6736(25)00629-4. PMID: 40543520. https://pubmed.ncbi.nlm.nih.gov/40543520/ This is a summary of trial findings, not an individual treatment recommendation. AI-narrated episode. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

After thyroidectomy for low-risk differentiated thyroid cancer, is omission of postoperative radioiodine non-inferior to ablation?In the IoN randomised trial, omission of postoperative radioiodine was noninferior to ablation for 5-year recurrence-free survival.Randomised multicentre non-inferiority trial · The Lancet 2025Reference: Mallick U, et al. Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN). Lancet. 2025;406(10498):52-62. doi:10.1016/S0140-6736(25)00629-4. PMID: 40543520. https://pubmed.ncbi.nlm.nih.gov/40543520/This is a summary of trial findings, not an individual treatment recommendation.AI-narrated episode. For healthcare professionals; educational only and not medical advice.Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

IoN: Skip radioiodine? | Hormone Insight Podcast

Does rosiglitazone increase myocardial infarction or cardiovascular-death risk in type 2 diabetes? A 2007 meta-analysis found a higher risk of myocardial infarction than control, with a borderline increase in cardiovascular death. Meta-analysis · New England Journal of Medicine 2007Reference: Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471. AI-narrated episode. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does rosiglitazone increase myocardial infarction or cardiovascular-death risk in type 2 diabetes?A 2007 meta-analysis found a higher risk of myocardial infarction than control, with a borderline increase in cardiovascular death.Meta-analysis · New England Journal of Medicine 2007Reference: Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.AI-narrated episode. For healthcare professionals; educational only and not medical advice.Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Rosiglitazone: A heart attack signal? | Hormone Insight Podcast

Does automated insulin delivery improve glucose control in children under 7 with type 1 diabetes? A 2026 meta-analysis reported improved time in range and HbA1c compared with standard care over 8 to 16 weeks. Meta-analysis · Diabetic Medicine 2026Reference: Lin Q, Zhou Y, Lei M, et al. Diabet Med. 2026;43(7):e70354. doi:10.1111/dme.70354. PMID:42108409. https://pubmed.ncbi.nlm.nih.gov/42108409/ Chapters0:00 Intro0:38 The study3:01 What this means3:31 Outro Read the structured trial summary at https://hormoneinsight.com/ AI-narrated. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does automated insulin delivery improve glucose control in children under 7 with type 1 diabetes?A 2026 meta-analysis reported improved time in range and HbA1c compared with standard care over 8 to 16 weeks.Meta-analysis · Diabetic Medicine 2026Reference: Lin Q, Zhou Y, Lei M, et al. Diabet Med. 2026;43(7):e70354. doi:10.1111/dme.70354. PMID:42108409. https://pubmed.ncbi.nlm.nih.gov/42108409/Chapters0:00 Intro0:38 The study3:01 What this means3:31 OutroRead the structured trial summary at https://hormoneinsight.com/AI-narrated. For healthcare professionals; educational only and not medical advice.Hormone Insight: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Closed-loop under 7: Automated insulin delivery | Hormone Insight Podcast

Does liraglutide reduce hospitalization risk compared with glimepiride in people with type 2 diabetes on metformin? In GRADE participants with type 2 diabetes on metformin, time to first hospitalization did not differ overall by glucose-lowering drug; liraglutide modestly reduced subsequent hospitalization risk versus glimepiride on assigned treatment. Secondary analysis of a randomised trial · Diabetes Care 2025Reference: Hsia DS, Younes N, Ghosh A. Diabetes Care. 2025. PMID: 40424051. https://pubmed.ncbi.nlm.nih.gov/40424051/ AI-narrated episode. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/iPhone/iPad app: https://apps.apple.com/sa/app/hormone-insight/id6749515856Android app: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does liraglutide reduce hospitalization risk compared with glimepiride in people with type 2 diabetes on metformin?In GRADE participants with type 2 diabetes on metformin, time to first hospitalization did not differ overall by glucose-lowering drug; liraglutide modestly reduced subsequent hospitalization risk versus glimepiride on assigned treatment.Secondary analysis of a randomised trial · Diabetes Care 2025Reference: Hsia DS, Younes N, Ghosh A. Diabetes Care. 2025. PMID: 40424051. https://pubmed.ncbi.nlm.nih.gov/40424051/AI-narrated episode. For healthcare professionals; educational only and not medical advice.Hormone Insight: https://hormoneinsight.com/iPhone/iPad app: https://apps.apple.com/sa/app/hormone-insight/id6749515856Android app: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

GRADE: Fewer admissions? Not so fast | Hormone Insight Podcast

Does tirzepatide improve kidney outcomes compared with insulin glargine in type 2 diabetes with high cardiovascular risk? In people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed eGFR decline and reduced albuminuria more than insulin glargine over a median 85 weeks. This was a secondary analysis of a randomised trial. Reference: Heerspink HJL, Sattar N, Pavo I, et al. Lancet Diabetes Endocrinol. 2022. PMID: 36152639. https://pubmed.ncbi.nlm.nih.gov/36152639/ AI-narrated episode. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/iPhone/iPad app: https://apps.apple.com/sa/app/hormone-insight/id6749515856Android app: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does tirzepatide improve kidney outcomes compared with insulin glargine in type 2 diabetes with high cardiovascular risk?In people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed eGFR decline and reduced albuminuria more than insulin glargine over a median 85 weeks. This was a secondary analysis of a randomised trial.Reference: Heerspink HJL, Sattar N, Pavo I, et al. Lancet Diabetes Endocrinol. 2022. PMID: 36152639. https://pubmed.ncbi.nlm.nih.gov/36152639/AI-narrated episode. For healthcare professionals; educational only and not medical advice.Hormone Insight: https://hormoneinsight.com/iPhone/iPad app: https://apps.apple.com/sa/app/hormone-insight/id6749515856Android app: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

SURPASS-4: Tirzepatide and the kidney | Hormone Insight Podcast

Does oral semaglutide reduce major adverse cardiovascular events in high-risk type 2 diabetes patients? In people with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, oral semaglutide reduced major adverse cardiovascular events compared with placebo. Randomized trial · NEJM 2025Reference: McGuire DK, Marx N, Mulvagh SL. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025; PMID:40162642. Chapters0:00 Intro0:38 The trial3:07 My take3:49 Outro Read the structured trial summary at https://hormoneinsight.com/ AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. Explore Hormone Insight:Website: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does oral semaglutide reduce major adverse cardiovascular events in high-risk type 2 diabetes patients?In people with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, oral semaglutide reduced major adverse cardiovascular events compared with placebo.Randomized trial · NEJM 2025Reference: McGuire DK, Marx N, Mulvagh SL. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025; PMID:40162642.Chapters0:00 Intro0:38 The trial3:07 My take3:49 OutroRead the structured trial summary at https://hormoneinsight.com/AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.Explore Hormone Insight:Website: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

SOUL: Oral semaglutide and the heart | Hormone Insight Podcast

Does weekly subcutaneous semaglutide 2.4 milligrams reduce cardiovascular events in patients with obesity without diabetes? In patients with established cardiovascular disease and overweight or obesity but without diabetes, once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events more than placebo. Randomized trial · NEJM 2023Reference: Lincoff AM, Brown-Frandsen K, Colhoun HM. N Engl J Med. 2023; PMID:37952131. Chapters0:00 Intro0:38 The trial3:05 My take3:42 Outro Read the structured trial summary at https://hormoneinsight.com/ AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. Explore Hormone Insight:Website: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does weekly subcutaneous semaglutide 2.4 milligrams reduce cardiovascular events in patients with obesity without diabetes?In patients with established cardiovascular disease and overweight or obesity but without diabetes, once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events more than placebo.Randomized trial · NEJM 2023Reference: Lincoff AM, Brown-Frandsen K, Colhoun HM. N Engl J Med. 2023; PMID:37952131.Chapters0:00 Intro0:38 The trial3:05 My take3:42 OutroRead the structured trial summary at https://hormoneinsight.com/AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.Explore Hormone Insight:Website: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

SELECT: Weight drug, heart benefit | Hormone Insight Podcast

Does once-weekly 2.4 milligram subcutaneous semaglutide plus lifestyle intervention reduce BMI more than lifestyle intervention alone in adolescents with obesity? In adolescents with obesity, once-weekly 2.4 mg subcutaneous semaglutide plus lifestyle intervention reduced BMI more than lifestyle intervention alone over 68 weeks, by about 17 percentage points. Randomized trial · NEJM 2022Reference: Weghuber D, Barrett T, Barrientos-Pérez M. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022; PMID:36322838. Chapters0:00 Intro0:38 The trial3:14 My take3:43 Outro Read the structured trial summary at https://hormoneinsight.com/ AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. Explore Hormone Insight:Website: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does once-weekly 2.4 milligram subcutaneous semaglutide plus lifestyle intervention reduce BMI more than lifestyle intervention alone in adolescents with obesity?In adolescents with obesity, once-weekly 2.4 mg subcutaneous semaglutide plus lifestyle intervention reduced BMI more than lifestyle intervention alone over 68 weeks, by about 17 percentage points.Randomized trial · NEJM 2022Reference: Weghuber D, Barrett T, Barrientos-Pérez M. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022; PMID:36322838.Chapters0:00 Intro0:38 The trial3:14 My take3:43 OutroRead the structured trial summary at https://hormoneinsight.com/AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.Explore Hormone Insight:Website: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

STEP TEENS: Semaglutide for teens | Hormone Insight Podcast

Can oral orforglipron preserve weight loss after stopping tirzepatide or semaglutide? In selected adults without diabetes, switching to orforglipron preserved more of their previous injectable-associated weight loss than switching to placebo over 52 weeks; continued injections were not compared. Randomized trial · Nature Medicine 2026Reference: Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32(7):2679–2687. First published 13 May 2026. doi:10.1038/s41591-026-04386-7. PMID:42120723. https://pubmed.ncbi.nlm.nih.gov/42120723/ Chapters0:00 Intro0:38 The trial3:31 My take4:01 Outro Read the structured trial summary at https://hormoneinsight.com/ AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. Explore Hormone Insight:Website: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Can oral orforglipron preserve weight loss after stopping tirzepatide or semaglutide?In selected adults without diabetes, switching to orforglipron preserved more of their previous injectable-associated weight loss than switching to placebo over 52 weeks; continued injections were not compared.Randomized trial · Nature Medicine 2026Reference: Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32(7):2679–2687. First published 13 May 2026. doi:10.1038/s41591-026-04386-7. PMID:42120723. https://pubmed.ncbi.nlm.nih.gov/42120723/Chapters0:00 Intro0:38 The trial3:31 My take4:01 OutroRead the structured trial summary at https://hormoneinsight.com/AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.Explore Hormone Insight:Website: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

ATTAIN-MAINTAIN: Keeping the weight off | Hormone Insight Podcast

Does withdrawal of once-weekly subcutaneous semaglutide 2.4 milligrams lead to weight regain and reversal of cardiometabolic benefits in adults with obesity? In adults with obesity, stopping semaglutide 2.4 mg led to regain of about two-thirds of lost weight and reversal of most cardiometabolic improvements by one year. Secondary analysis of RCT · Diabetes Obes Metab 2022Reference: Wilding JP, Batterham RL, Davies M. Diabetes Obes Metab. 2022; PMID:35441470 Chapters0:00 Intro0:38 The trial3:18 My take3:46 Outro Read the structured trial summary at https://hormoneinsight.com/ AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. Explore Hormone Insight:Website: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does withdrawal of once-weekly subcutaneous semaglutide 2.4 milligrams lead to weight regain and reversal of cardiometabolic benefits in adults with obesity?In adults with obesity, stopping semaglutide 2.4 mg led to regain of about two-thirds of lost weight and reversal of most cardiometabolic improvements by one year.Secondary analysis of RCT · Diabetes Obes Metab 2022Reference: Wilding JP, Batterham RL, Davies M. Diabetes Obes Metab. 2022; PMID:35441470Chapters0:00 Intro0:38 The trial3:18 My take3:46 OutroRead the structured trial summary at https://hormoneinsight.com/AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.Explore Hormone Insight:Website: https://hormoneinsight.com/Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

STEP-1: What happens when you stop? | Hormone Insight Podcast

Discuss Diabetes and Endocrinology studies in a simplified manner. Expand your knowledge in Diabetes and Endocrinology.

Discuss Diabetes and Endocrinology studies in a simplified manner. Expand your knowledge in Diabetes and Endocrinology.

hubhopper

Hormone Insight

hubhopper